US2019224307A1PendingUtilityA1

Rabies glycoprotein virus-like particles (vlps)

57
Assignee: NOVAVAX INCPriority: Nov 5, 2010Filed: Aug 30, 2018Published: Jul 25, 2019
Est. expiryNov 5, 2030(~4.3 yrs left)· nominal 20-yr term from priority
Inventors:Gale SmithYe Liu
A61P 31/12A61P 31/14A61P 37/04A61P 31/16A61K 2039/55505A61K 39/12C12N 2799/026C07K 14/005A61K 2039/5258A61K 39/205C12N 2760/20134A61K 9/127
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention is generally related to virus-like particles (VLPs) comprising rabies virus (RV) glycoproteins (G proteins) and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of rabies virus infection.

Claims

exact text as granted — not AI-modified
1 . A purified micelle comprising one or more rabies virus (RV) glycoproteins (G proteins). 
     
     
         2 . The purified micelle of  claim 1 , wherein the RV G protein is derived from a RV strain selected from human, canine, bat, raccoon, skunk, and fox. 
     
     
         3 . A virus-like particle (VLP) comprising a RV G protein. 
     
     
         4 . The VLP of  claim 3 , wherein the RV G protein is derived from a RV strain selected from human, canine, bat, raccoon, skunk, and fox. 
     
     
         5 . The VLP of  claim 3 , wherein the VLP comprises a matrix (M) protein. 
     
     
         6 . The VLP of  claim 5 , wherein said M protein is derived from RV. 
     
     
         7 . The VLP of  claim 5 , wherein said M protein is M1 from an influenza virus strain. 
     
     
         8 . The VLP of  claim 5 , wherein said influenza virus strain is an avian influenza virus strain. 
     
     
         9 . The VLP of  claim 8 , wherein said avian influenza virus strain is an H5N1 strain. 
     
     
         10 . The VLP of  claim 9 , wherein said H5N1 strain is A/Indonesia/5/05. 
     
     
         11 . The VLP of  claim 5 , wherein said M protein is derived from a Newcastle Disease Virus (NDV) strain. 
     
     
         12 . The VLP of  claim 3 , wherein the VLP is expressed in a eukaryotic cell under conditions which permit the formation of VLPs. 
     
     
         13 . The VLP of  claim 12 , wherein the eukaryotic cell is selected from the group consisting of yeast, insect, amphibian, avian, mammalian, or plant cells. 
     
     
         14 . (canceled) 
     
     
         15 . An immunogenic composition comprising a VLP according to  claim 3 . 
     
     
         16 .- 17 . (canceled) 
     
     
         18 . A kit for immunizing a human subject against a viral infection comprising a purified micelle according to  claim 1 . 
     
     
         19 . A kit for immunizing a human subject against a viral infection comprising a VLP according to  claim 3 . 
     
     
         20 . The kit according to  claim 18 , wherein the viral infection is a RV infection. 
     
     
         21 .- 26 . (canceled) 
     
     
         27 . An isolated nucleic acid encoding a RV G protein of SEQ ID NO: 2. 
     
     
         28 . An isolated cell comprising a nucleic acid of  claim 27 . 
     
     
         29 . A vector comprising the nucleic acid of  claim 27 . 
     
     
         30 .- 33 . (canceled)

Join the waitlist — get patent alerts

Track US2019224307A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.